ArticleBiochemistry and biophysics reports2026
Exploration of the multi-component, multi-target, and multi-pathway mechanism of
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is a malignancy associated with high morbidity and mortality. Objective: This study investigated the effect of RY on BC and elucidated its underlying molecular regulatory mechanisms. Methods: The role of RY in BC was assessed through CCK-8, Transwell, flow cytometry, Western blot, xenograft modeling, and immunohistochemistry assays. We employed ultra-high-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF/MS), the PubChem and TCMSP database, and literature mining to identify the active ingredients of RY. Potential targets for these active ingredients were predicted using TargetPrediction database, while BC-regulated targets were collected from the GeneCards, DrugBank, and TTD databases. A protein-protein interaction network analysis identified core targets, followed by GO and KEGG enrichment analyses using the DAVID database. Molecular docking was performed to validate the binding affinity of the active ingredients for these core targets. Finally, Western blot analysis was used to detect the relative protein expression levels of the core targets. Results: RY significantly reduced the viability of MDA-MB-231 and BT-549 cells, inhibited their migratory capacity, promoted apoptosis, and upregulated the expression of the E-cadherin, while downregulating the expression of N-cadherin and vimentin. These effects were concentration-dependent. In vivo studies demonstrated that RY treatment inhibited BC growth, reduced the Ki67-positive rate and the expression of N-cadherin and vimentin in mouse BC tissues, and promoted the expression of E-cadherin. Furthermore, UPLC-Q-TOF/MS analysis and database mining identified 26 active components in RY and 312 potential targets related to its action against BC. The core targets for RY in BC treatment include Conclusion: This study reveals that RY exhibits therapeutic potential on BC through multi-ingredient, multi-target, and multi-pathway mode of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.